| http://www.w3.org/ns/prov#value | - FluoroPharma, a developer of specialized molecular imaging pharmaceuticals used with positron emission tomography (PET) to help detect heart disease and other problems, has stated that it intends to develop its products through the completion of phase II and/or phase III studies, at which point it will seek to partner with organizations that may facilitate the further development and distribution
|
